Analyst Reco. CytomX Therapeutics, Inc.

Equities

CTMX

US23284F1057

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
1.59 ^USD	-0.62%		-4.79%	+2.58%

04-22	JPMorgan Upgrades CytomX Therapeutics to Neutral From Underweight	MT
04-08	CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Upgrades CytomX Therapeutics to Neutral From Underweight	04-22	MT
BMO Capital Adjusts CytomX Therapeutics Price Target to $3.25 From $3.30, Maintains Market Perform Rating	03-12	MT
Wedbush Lifts CytomX Therapeutics' PT to $3 From $2, Says Focused Pipeline Moving Forward; Keeps Neutral Rating	11-09	MT
BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.19 From $3.15, Keeps Market Perform Rating	09/08/23	MT
Mizuho Securities Adjusts CytomX Therapeutics Price Target to $2 From $4, Maintains Neutral Rating	28/03/23	MT
BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.20 From $2.60, Maintains Market Perform Rating	06/01/23	MT
BMO Capital Downgrades CytomX Therapeutics to Market Perform From Outperform, Adjusts Price Target to $2.60 From $3	14/11/22	MT
JPMorgan Downgrades CytomX Therapeutics to Underweight From Overweight	10/11/22	MT
Cowen Downgrades CytomX Therapeutics to Market Perform From Outperform	11/07/22	MT
HC Wainwright Downgrades CytomX Therapeutics to Neutral From Buy	11/07/22	MT
Jefferies Downgrades CytomX Therapeutics to Hold From Buy, Lowers Price Target to $2 From $12	07/07/22	MT
Piper Sandler Downgrades CytomX Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.50 From $10	07/07/22	MT
BTIG Lowers CytomX Therapeutics' Price Target to $8 From $16, Buy Rating Kept	07/07/22	MT
BMO Capital Lowers CytomX Therapeutics' Price Target to $3 From $9, Outperform Rating Maintained	07/07/22	MT
Barclays Adjusts CytomX Therapeutics' Price Target to $3.50 From $7, Keeps Overweight Rating	07/07/22	MT
Wedbush Cuts CytomX Therapeutics to Neutral From Outperform, Price Target to $2 From $6, Citing Praluzatamab Ravtansine Update, 'Tough Financing Environment'	07/07/22	MT
Piper Sandler Cuts CytomX Therapeutics to Neutral From Overweight, Price Target to $1.50 From $10	07/07/22	MT
Mizuho Securities Cuts CytomX Therapeutics to Neutral From Buy, Price Target to $4 From $16	07/07/22	MT
BMO Capital Starts CytomX Therapeutics at Outperform With $9 Price Target	24/06/22	MT
Piper Sandler Adjusts Price Target on CytomX Therapeutics to $10 From $16, Reiterates Overweight Rating	31/05/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. CytomX Therapeutics, Inc.

Equities

CTMX

US23284F1057

Analyst Reco.

Filters